The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study-Reference-Cited by-同舟云学术

The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study

Published:2013-11-15 Issue:2 Volume:63 Page:147-160
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

de Vos van Steenwijk Peggy J.,van Poelgeest Mariette I. E.,Ramwadhdoebe Tamara H.,Löwik Margriet J. G.,Berends-van der Meer Dorien M. A.,van der Minne Caroline E.,Loof Nikki M.,Stynenbosch Linda F. M.,Fathers Lorraine M.,Valentijn A. Rob P. M.,Oostendorp Jaap,Osse Elisabeth M.,Fleuren Gert Jan,Nooij Linda,Kagie Marjolein J.,Hellebrekers Bart W. J.,Melief Cornelis J. M.,Welters Marij J. P.,van der Burg Sjoerd H.,Kenter Gemma G.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-013-1499-2.pdf

Reference31 articles.

1. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121:621–632

2. Schiffman M, Kjaer SK (2003) Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 31:14–19

3. Murdoch JB, Morgan PR, Lopes A, Monaghan JM (1992) Histological incomplete excision of CIN after large loop excision of the transformation zone (LLETZ) merits careful follow up, not retreatment. Br J Obstet Gynaecol 99:990–993

4. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E (2006) Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 367:489–498

5. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE, Lowy DR (2007) Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298:743–753

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancement of HPV therapeutic peptide-based vaccine efficacy through combination therapies and improved delivery strategies: A review;Human Vaccines & Immunotherapeutics;2024-08-28

2. Immunotherapy in Cervical and Endometrial Cancer: Current Landscape and Future Directions;Life;2024-03-06

3. A new frontier in cancer therapy: The intersection of cancer vaccines and metabolomics;Metabolomics for Personalized Vaccinology;2024

4. Epidemiology, Molecular Pathogenesis, Immuno-Pathogenesis, Immune Escape Mechanisms and Vaccine Evaluation for HPV-Associated Carcinogenesis;Pathogens;2023-11-23

5. Breast cancer vaccination: Latest advances with an analytical focus on clinical trials;International Immunopharmacology;2023-10